Full Press Release Details
Announces Two Successful Live Clinical Case Transmissions Featuring CGuard EPS at the Leipzig Interventional Course
demonstrate ease-of-use of CGuard EPS in two challenging clinical situations physicians face when treating carotid artery
Aviv, Israel - January 23, 2019 - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic
Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that two
successful live cases featuring CGuard EPS were presented at LINC 2019, which is being held January 21 - 23 in Leipzig,
live demonstrations of CGuard EPS at this year's LINC conference, a major international interventional conference
covering the latest innovations in vascular medicine, allowed attending physicians to see first-hand the simplicity of the CGuard
EPS procedure as conducted by world renowned interventional cardiologists and angiologists," said Dr. James Barry, President
and Chief Executive Officer of InspireMD. "It is immensely gratifying to once again have CGuard EPS chosen by these
leading interventionalists to be prominently featured in two live case transmissions today at LINC 2019."
case #1: Patient with Symptomatic Left Carotid Artery Disease and Concomitant Coronary Artery Disease
first live case was conducted by Dr. Antonio Micari and Dr. Fausto Castriota, interventional cardiologists at Humanitas Gavazzeni
Hospital, Bergamo, Italy. The patient had stable angina over the prior twelve months, with one hospital admission for one transient
ischemic attack (TIA) approximately one month ago. The risk factors included hypertension, hypercholesterolemia and critical left
interior carotid artery (LICA) stenosis with evidence of soft plaque. The procedure was successfully performed with the 8mm x
40mm CGuard EPS, lasted approximately 20 minutes and had an excellent angiographic result.
the procedure, Drs. Micari and Castriota commented, "This patient presented with multiple co-morbidities, including a history
of transient ischemic attacks, and a large amount of soft plaque that significantly increases the chance of embolization associated
with conventional carotid stents. There were no adverse events during the procedure. At this early stage, it appears that CGuard
EPS offers superior patient protection where conventional carotid stents may not."
case #2: Restenosis of the Left Common Carotid Artery after TEA
second live case was conducted by Drs. Andre Schmidt and Matthias Ullrich of Universitaetsklinikum of Leipzig, in Leipzig, Germany.
The patient was symptomatic with a high grade stenosis of the right common carotid artery, likely caused by post radiation and
open surgery due to a parotid tumor, and had dizziness. The risk factors included hypertension, hyperlipidemia and the patient
is a former smoker. The patient received a 8mm x 40mm CGuard EPS and the case also lasted approximately 20 minutes with
an excellent angiographic result.
the procedure, Drs. Schmidt and Ullrich commented, "We were very happy with the performance of the CGuard in today's
challenging case that is not seen in everyday practice. It continues to reinforce our positive impressions of this innovative
product and we look forward to continuing to implement it in our practice."
is a leading global forum for new methods in the field of vascular medicine. LINC brings together medical professionals from different
specialties around the world who perform endovascular interventions.
seeks to utilize its proprietary MicroNet technology to make its products the industry standard for treatment of carotid
artery disease by providing outstanding acute results and durable stroke free long-term outcomes.
common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American
under the ticker symbol NSPR.WS.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are
subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot
be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance
of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability
to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much
larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities
and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third
party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering
our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and
foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need
to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive
or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign
currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws
and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors
that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities
and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information,
future events or otherwise.